Literature DB >> 1457425

Interleukin-6, a marker of preservation injury in clinical lung transplantation.

S M Pham1, Y Yoshida, R Aeba, B G Hattler, Y Iwaki, A Zeevi, R L Hardesty, B P Griffith.   

Abstract

Interleukin-6 (IL-6) is one of the cytokines produced by human alveolar macrophages, lung parenchyma, and other cells in response to injury and infection. We hypothesized that IL-6 is released from poorly preserved lung grafts and may serve as a marker of preservation injury. Sixteen patients who received lung allografts were enrolled in this study. The average ischemic time was 284 +/- 78 minutes. Serum IL-6 level was measured before and at 4 and 24 hours after reperfusion of the grafts by an enzyme-linked immunosorbent assay. Preservation injury was assessed by (1) the need for prolonged intubation (> 7 days), (2) the arterial/alveolar oxygen tension ratio (PaO2/PAO2 ratio) at 4 hours after graft reperfusion (only in heart-lung or double lung recipients), (3) the presence of diffuse alveolar damage on first lung biopsy, and (4) the 30-day graft survival rate. IL-6 level peaked at 4 hours after reperfusion and returned to baseline at 24 hours. The patients were divided into group I (n = 6) and group II (n = 10), depending on whether the 4-hour IL-6 level was more than 1000 pg/ml or less than 500 pg/ml, respectively. Group I patients required longer intubation (p < 0.01) and had a lower PaO2/PAO2 ratio (p < 0.001), more diffuse alveolar damage (p < 0.01), and a lower graft survival rate (p < 0.01) than those of group II. No bacterial, fungal, or viral infection was found during postoperative week 1 in either group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1457425

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  8 in total

1.  Mediators of ischemia-reperfusion injury of rat lung.

Authors:  M J Eppinger; G M Deeb; S F Bolling; P A Ward
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 2.  Selecting lung transplant candidates: where do current guidelines fall short?

Authors:  Jaime L Hook; David J Lederer
Journal:  Expert Rev Respir Med       Date:  2012-02       Impact factor: 3.772

3.  Immediate postoperative inflammatory response predicts long-term outcome in lung-transplant recipients.

Authors:  David J Hall; Maher Baz; Michael J Daniels; Edward Denmark Staples; Charles T Klodell; Lyle L Moldawer; Thomas M Beaver
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-07-19

Review 4.  Primary graft dysfunction.

Authors:  Yoshikazu Suzuki; Edward Cantu; Jason D Christie
Journal:  Semin Respir Crit Care Med       Date:  2013-07-02       Impact factor: 3.119

5.  The effects of exogenous interleukin-4 on hypoxia-induced lung injury.

Authors:  Hayrettin Ozturk; Hulya Ozturk; Huseyin Buyukbayram; Mehmet Cudi Tuncer
Journal:  Pediatr Surg Int       Date:  2006-01-20       Impact factor: 1.827

6.  Cytokine mRNA expression in endomyocardial biopsies during acute rejection from human heart transplants.

Authors:  C C Baan; N E van Emmerik; A H Balk; W G Quint; B Mochtar; N H Jutte; H G Niesters; W Weimar
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

7.  Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation.

Authors:  Carolyn S Calfee; Marie M Budev; Michael A Matthay; Gwynne Church; Sandra Brady; Tokujiro Uchida; Akitoshi Ishizaka; Abigail Lara; Justin L Ranes; Malcom M deCamp; Alejandro C Arroliga
Journal:  J Heart Lung Transplant       Date:  2007-07       Impact factor: 10.247

8.  First Experience With Extracorporeal Cytokine Adsorption Therapy After Lung Transplantation.

Authors:  Marine Peyneau; Luc de Chaisemartin; Dorothée Faille; Jonathan Messika; Hervé Mal; Yves Castier; Pierre Mordant; José Luis Carrasco; Sébastien Tanaka; Brice Lortat Jacob; Paola Ferrari; Xavier Arrault; Nadine Ajzenberg; Sylvie Chollet-Martin; Philippe Montravers; Alexy Tran-Dinh
Journal:  Transpl Int       Date:  2022-03-21       Impact factor: 3.782

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.